ArQule and Daiichi Sankyo have signed a special protocol assessment (SPA) agreement with the FDA for Phase 3 trial of Tivantinib in hepatocellular carcinoma (HCC). The SPA process enables FDA to offer official evaluation and written ...
Tags: ArQule, Daiichi Sankyo, SPA, FDA